The primary objective of the trial was to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN when administered intratumourally to patients receiving radiation treatment. A secondary objective was to examine any evidence of anti-tumour activity. The treatment was well tolerated in all cohorts, with no DLTs, and no MTD was reached.
"This is an early study but the absence of any significant side-effects is extremely reassuring for future trials in patients receiving radiotherapy with the aim of curing their cancer," said Dr. Harrington.
About The Institute of Cancer Research (ICR)
- The ICR is Europe's leading cancer research centre - The ICR has been ranked the UK's top academic research centre, based on the results of the Higher Education Funding Council's Research Assessment Exercise - The ICR works closely with partner The Royal Marsden NHS Foundation Trust to ensure patients immediately benefit from new research. Together the two organisations form the largest comprehensive cancer centre in Europe - The ICR has charitable status and relies on voluntary income, spending 95 pence in every pound of total income directly on research - As a college of the University of London, the ICR also provides postgraduate higher education of international distinction - Over its 100-year history, the ICR's achievements include identifying the potential link between smoking and lung cancer which was subsequently confirmed, discovering that DNA damage is the basic
|SOURCE Oncolytics Biotech Inc.|
Copyright©2010 PR Newswire.
All rights reserved